Introduction
============

Gastrointestinal neuroendocrine tumors (GI-NETs) are rare tumors. Gastric NETs (G-NETs) and duodenal NETs (D-NETs) are considered the most common upper GI-NETs [@JR1763-1] . Diagnosis of these lesions is currently on the rise, due to widespread utilization of upper endoscopy and improvements in classification of these tumors.

Regardless of the type (G-NETs or D-NETs), endoscopic resection is recommended as an initial treatment for tumors that are not yet at advanced stages [@JR1763-2] [@JR1763-3] . Surgery is recommended for all advanced cases either as an initial therapy or following endoscopic resection [@JR1763-3] [@JR1763-4] .

GI-NETs eligible for endoscopic management are those of small tumor size (Type I G-NETs ≤ 10 mm and D-NETs ≤ 10 mm) as they are less likely to be associated with muscularis propria invasion or metastasis [@JR1763-3] [@JR1763-4] [@JR1763-5] [@JR1763-6] . Current endoscopic techniques, both endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), are alternatives to surgical management but are associated with risk of adverse events (AEs) including bleeding, perforation and stricture formation secondary to electrocautery use [@JR1763-7] . These risks are even higher with tumors of the duodenal bulb due to the thin duodenal wall and its increased vasculature.

The band and slough (BAS) technique, also known as endoscopic band ligation without resection (BWR), has been used for the management of mucosal lesions in the gastrointestinal tract with varying degrees of success ranging from 75 % to 100 % [@JR1763-8] . We have previously reported outcomes of the BAS technique in management of non-ampullary duodenal adenomas without the use of electrocautery [@JR1763-9] . The BAS technique works by compressive tissue ischemia resulting in adenoma sloughing off without the use of electrocautery. Thus, reducing risk of AEs associated with EMR and ESD. This technique has not been thoroughly evaluated for management of gastric and duodenal neuroendocrine tumors. Accordingly, we examined outcomes of the BAS technique as a novel and less aggressive endoscopic method to effectively manage diminutive (≤ 10 mm) gastric and duodenal neuroendocrine tumors.

Patients and methods
====================

Patients
--------

The study was approved by the St. Joseph Mercy Ann Arbor Hospital Institutional Review Board. All eligible patients were adults of age 18 years or older with biopsy proven, low grade (G1), and non-metastatic Type 1 G-NETs ≤ 10 mm and D-NETs ≤ 10 mm. Patients with metastatic disease evident on multislice computed tomography scan (regional lymph node and/or distant metastasis), poor histological differentiation, high grade (G2--G3), G-NETs \> 10 mm, type II and III G-NETs or D-NETs \> 10 mm were excluded from the study. Before the endoscopic procedure, diagnosis of NETs was confirmed by a biopsy consistent with a low grade (G1), well-differentiated NET. As per ENETS consensus guidelines for management of gastroduodenal neuroendocrine tumors, endoscopic ultrasonography (EUS) was conducted for type 1 G-NETs to assess the depth of invasion and regional metastasis [@JR1763-4] . However, EUS was not performed in the included patients with D-NETs given the small tumor size ≤ 10 mm [@JR1763-3] .

Methods
-------

Risks and benefits of the BAS technique versus EMR or ESD were discussed with the patients prior to the procedure and an informed consent was obtained. All procedures were performed by a single endoscopist on an outpatient basis, with the patient under conscious sedation. The neuroendocrine tumors were assessed for absence of alarming features (eg, small size, non-ulcerated, absence of central depression). Polyp size was estimated based on visual assessment ( [Fig. 1](#FI1763-1){ref-type="fig"} ).

![Endoscopic view of gastrointestinal neuroendocrine tumor in the duodenal bulb.](10-1055-a-1119-6698-i1763ei1){#FI1763-1}

The Speedband Superview Super (Boston Scientfic, Natick, Massachusetts, United States) banding kit was fitted onto a gastroscope in a standard fashion. The tumor was suctioned into the cap, and rubber bands were deployed at its base. Up to four bands were placed at the discretion of the endoscopist. When more than one band was placed at a site, the second band was deployed deeper to the first band. This resulted in forming a prominent pseudopolyp ( [Fig. 2](#FI1763-2){ref-type="fig"} ). Endoscopic resection was not performed and the polyp was allowed to slough off spontaneously. Location of the GI-NET after banding was marked with submucosal India ink injection to facilitate surveillance for residual disease and tumor recurrence.

![Pseudopolyp formation after band placement.](10-1055-a-1119-6698-i1763ei2){#FI1763-2}

Patients were observed for 60 minutes for acute post-procedure adverse events. They were subsequently discharged home when no immediate adverse events were noted. Patients were also contacted via a telephone call by an endoscopy nurse after 24 hours to identify any adverse events that were not noted immediately after the procedure.

Follow-up endoscopic assessment was performed at 3 months for all patients with a repeat upper gastrointestinal endoscopy ( [Fig. 3](#FI1763-3){ref-type="fig"} ). During which, the treatment site was identified by the tattoo and examined carefully by the endoscopist followed by extensive biopsies to assess for any residual disease. Surveillance endoscopy was then scheduled at a 12-month follow-up interval.

![Complete eradication of the neuroendocrine tumor at 3 months after a single banding session.](10-1055-a-1119-6698-i1763ei3){#FI1763-3}

The primary end point was complete histopathologic remission of GI-NETs confirmed by an expert gastrointestinal pathologist at 3-month follow-up ( [Fig. 4](#FI1763-4){ref-type="fig"} ).

![Well-differentiated neuroendocrine tumor in duodenal submucosa, 10 × magnification. **b** Non-neoplastic duodenal mucosa with benign submucosal glands on biopsy obtained at 3-month surveillance, 5 × magnification.](10-1055-a-1119-6698-i1763ei4){#FI1763-4}

Results
=======

Patients and GI-NET characteristics
-----------------------------------

Four patients with an established diagnosis of GI-NET referred for therapy between 2015 and 2018 met the study inclusion criteria and subsequently underwent the BAS technique. All patients had a prior upper endoscopy conducted for evaluation of dysphagia, abdominal pain, or diarrhea. Initial endoscopy revealed incidental findings of polypoidal lesions in the gastric fundus or the duodenal bulb with biopsies consistent with NETs. One patient was diagnosed with a 10-mm, G1, well-differentiated, type 1 G-NET. EUS revealed submucosal extension without invasion into the muscularis propria. The tumor was uniquely located within the gastric fundus, 2 cm beyond the gastroesophageal junction which was technically challenging for EMR or ESD to be performed. The remaining three patients were diagnosed with \< 10 mm, G1, well-differentiated and non-functioning, D-NETs located in the duodenal bulb. EUS was not performed given the small size of the D-NETs and the low histological grade. However, none of the patients had evidence of local or distant metastasis on multislice CT scan.

Patients and GI-NET characteristics, specifics of the procedures and outcomes are summarized in [Table 1](#TB1763-1){ref-type="table"} .

###### Patient and GI-NET characteristics and specifics of the procedure.

  -------------------------------------------- -------------
  Number of patients                            4
  Male, %                                      50
  Patient age, average (range), years          70 (66--77)
  GI-NETs Size, mean (range), mm                8 (6--10)
  Location of GI-NET, no. of patients          
  Gastric Fundus                                1
  Duodenal Bulb                                 3
  Findings, no. of patients                    
  Type I G-NET                                  1
  D-NET                                         3
  No. of banding sessions per patient           1
  No. of bands deployed per session, mean       2.75
  No. of patients at each follow-up interval   
  3 months                                      4
  12 months                                     4
  24 months                                     1
  -------------------------------------------- -------------

GI-NET gastric neuroendocrine tumor; D-NET, duodenal neuroendocrine tumor

Treatment outcomes
------------------

Complete remission of the GI-NET was achieved in 100 % of patients at 3 months follow-up, with only one session of banding. All patients have completed their 12-month follow-up without evidence of tumor recurrence on repeat upper endoscopy.

Adverse events
--------------

There was no bleeding, pain, perforation, or stricture formation after any intervention.

Discussion
==========

This study demonstrates that the BAS technique is a safe and effective endoscopic treatment for diminutive (≤ 10 mm), type 1 G-NETs and D-NETs. This is evident by the complete eradication of the GI-NET at 3-month follow-up after one session of banding only.

The BAS technique works by compressive tissue ischemia resulting in sloughing off and eradication of the tumor. Applying one band only is usually sufficient to induce the compressive tissue ischemia and is associated with lower risks of gastroduodenal wall tear and bleeding. In addition, endoscopic band ligation can effectively remove submucosal tumors and can also capture tumors originating from the muscularis propria without the use of electrocautery [@JR1763-10] . Therefore, it is expected to be associated with lower risks of bleeding, transmural injury and perforation which are known adverse events to EMR or ESD [@JR1763-7] . These risks are more pronounced with duodenal lesions as compared to gastric lesions which can be attributed to the thin duodenal wall and its increased vascularity. However, the BAS technique can also offer a safer endoscopic approach for gastric lesions that are technically challenging to undergo EMR or ESD due to difficult locations with increased risk of procedure-related AEs. Furthermore, the BAS technique offers more feasibility when compared to EMR or ESD as it does not require advanced endoscopy training and can be performed by a general gastroenterologist. Fortunately, all patients were able to be discharged home directly after the procedure with no need for hospitalization. No immediate, early or delayed post-procedure adverse events were reported for any of the patients.

The main limitations of the study are the small sample size given the rare nature of GI-NETs, need for longer follow-up periods, and lack of direct comparison to endoscopic resection techniques. Therefore, it is difficult to prove superiority or non-inferiority of the BAS technique. Further limitations include inability to assess the deep margins of the resection and lack of tissue retrieval at the time of therapy. This raises the concern for increased risk of residual disease and tumor recurrence. However, the diagnoses of GI-NETs were based on previously obtained biopsies, confirmed by an expert gastrointestinal pathologist. In addition, the tumors were carefully examined by the endoscopist for any signs of tumor invasion or malignant potential. Furthermore, close endoscopic follow-up was ensured to minimize the risk of missing a residual or recurrent tumor. In our patients, no residual or recurrent tumor was noted in any of the scheduled follow-up visits.

The success of the BAS technique is further demonstrated by the histological remission of GI-NETs with up to 12-month follow-up in D-NET patients and up to 24-month follow-up in our type 1 G-NET patient. Patients are currently scheduled for their follow-up endoscopic examination according to ENETS guidelines. Thus far, no acute or delayed AEs related to the procedure were observed in our patients.

Conclusion
==========

In conclusion, the band and slough endoscopic technique may prove to be a safe, less aggressive, and effective alternative to endoscopic mucosal resection and endoscopic submucosal dissection in management of diminutive (≤ 10 mm), low-grade (G1), well-differentiated, type 1 gastric neuroendocrine tumors and duodenal neuroendocrine tumors. Studies of larger scale and longer follow-up periods are needed to corroborate these findings.
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